Novartis AG (NOVN.SW)
| Previous close | 88.10 |
| Open | 88.26 |
| Bid | 89.68 x 0 |
| Ask | 89.69 x 0 |
| Day's range | 88.07 - 89.81 |
| 52-week range | 79.21 - 94.52 |
| Volume | |
| Avg. volume | 3,233,072 |
| Market cap | 182.943B |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | 22.53 |
| EPS (TTM) | 3.98 |
| Earnings date | 18 Jul 2024 |
| Forward dividend & yield | 3.30 (3.75%) |
| Ex-dividend date | 07 Mar 2024 |
| 1y target est | 86.92 |
GlobeNewswireArvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for
The TelegraphQuestor: this medical stock is expensive – but worth paying for
It’s a stock market rule of thumb that big acquisitions tend to destroy shareholder value. Spin-offs, on the other hand, have the reassuring habit of being more likely to create it.
ZacksAlnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
